167 related articles for article (PubMed ID: 33806305)
21. Heme: a regulator of rat hepatic tryptophan 2,3-dioxygenase?
Ren S; Correia MA
Arch Biochem Biophys; 2000 May; 377(1):195-203. PubMed ID: 10775460
[TBL] [Abstract][Full Text] [Related]
22. Tryptophan-2,3-dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptor-4.
Ochs K; Ott M; Rauschenbach KJ; Deumelandt K; Sahm F; Opitz CA; von Deimling A; Wick W; Platten M
J Neurochem; 2016 Mar; 136(6):1142-1154. PubMed ID: 26708701
[TBL] [Abstract][Full Text] [Related]
23. Heme-containing enzymes and inhibitors for tryptophan metabolism.
Yan D; Lin YW; Tan X
Metallomics; 2017 Sep; 9(9):1230-1240. PubMed ID: 28650043
[TBL] [Abstract][Full Text] [Related]
24. Systemic tryptophan homeostasis.
Klaessens S; Stroobant V; De Plaen E; Van den Eynde BJ
Front Mol Biosci; 2022; 9():897929. PubMed ID: 36188218
[TBL] [Abstract][Full Text] [Related]
25. Antimicrobial and immunoregulatory properties of human tryptophan 2,3-dioxygenase.
Schmidt SK; Müller A; Heseler K; Woite C; Spekker K; MacKenzie CR; Däubener W
Eur J Immunol; 2009 Oct; 39(10):2755-64. PubMed ID: 19637229
[TBL] [Abstract][Full Text] [Related]
26. The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment.
Gostner JM; Becker K; Überall F; Fuchs D
Expert Opin Ther Targets; 2015 May; 19(5):605-15. PubMed ID: 25684107
[TBL] [Abstract][Full Text] [Related]
27. Indoleamine 2,3-Dioxygenase Activity-Induced Acceleration of Tumor Growth, and Protein Kinases-Related Novel Therapeutics Regimens.
Engin AB; Engin A
Adv Exp Med Biol; 2021; 1275():339-356. PubMed ID: 33539022
[TBL] [Abstract][Full Text] [Related]
28. Tryptophan 2,3-Dioxygenase Expression Identified in Human Hepatocellular Carcinoma Cells and in Intratumoral Pericytes of Most Cancers.
Hoffmann D; Dvorakova T; Stroobant V; Bouzin C; Daumerie A; Solvay M; Klaessens S; Letellier MC; Renauld JC; van Baren N; Lelotte J; Marbaix E; Van den Eynde BJ
Cancer Immunol Res; 2020 Jan; 8(1):19-31. PubMed ID: 31806639
[TBL] [Abstract][Full Text] [Related]
29. Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme.
Triplett TA; Garrison KC; Marshall N; Donkor M; Blazeck J; Lamb C; Qerqez A; Dekker JD; Tanno Y; Lu WC; Karamitros CS; Ford K; Tan B; Zhang XM; McGovern K; Coma S; Kumada Y; Yamany MS; Sentandreu E; Fromm G; Tiziani S; Schreiber TH; Manfredi M; Ehrlich LIR; Stone E; Georgiou G
Nat Biotechnol; 2018 Sep; 36(8):758-764. PubMed ID: 30010674
[TBL] [Abstract][Full Text] [Related]
30. The expanding roles of 1-methyl-tryptophan (1-MT): in addition to inhibiting kynurenine production, 1-MT activates the synthesis of melatonin in skin cells.
Moreno AC; Clara RO; Coimbra JB; Júlio AR; Albuquerque RC; Oliveira EM; Maria-Engler SS; Campa A
FEBS J; 2013 Oct; 280(19):4782-92. PubMed ID: 23879623
[TBL] [Abstract][Full Text] [Related]
31. Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers.
Komiya T; Huang CH
Front Oncol; 2018; 8():423. PubMed ID: 30338242
[TBL] [Abstract][Full Text] [Related]
32. The effects of an inhibitor of tryptophan 2,3-dioxygenase and a combined inhibitor of tryptophan 2,3-dioxygenase and 5-HT reuptake in the rat.
Salter M; Hazelwood R; Pogson CI; Iyer R; Madge DJ; Jones HT; Cooper BR; Cox RF; Wang CM; Wiard RP
Neuropharmacology; 1995 Feb; 34(2):217-27. PubMed ID: 7617147
[TBL] [Abstract][Full Text] [Related]
33. Analysis of Reaction Intermediates in Tryptophan 2,3-Dioxygenase: A Comparison with Indoleamine 2,3-Dioxygenase.
Basran J; Booth ES; Lee M; Handa S; Raven EL
Biochemistry; 2016 Dec; 55(49):6743-6750. PubMed ID: 27951658
[TBL] [Abstract][Full Text] [Related]
34. A comprehensive comparison of the metazoan tryptophan degrading enzymes.
Yuasa HJ
Biochim Biophys Acta Proteins Proteom; 2020 Jan; 1868(1):140247. PubMed ID: 31276825
[TBL] [Abstract][Full Text] [Related]
35. Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors activate the aryl hydrocarbon receptor.
Moyer BJ; Rojas IY; Murray IA; Lee S; Hazlett HF; Perdew GH; Tomlinson CR
Toxicol Appl Pharmacol; 2017 May; 323():74-80. PubMed ID: 28336214
[TBL] [Abstract][Full Text] [Related]
36. Skin L-tryptophan-2,3-dioxygenase and rat hair growth.
Ishiguro I; Naito J; Saito K; Nagamura Y
FEBS Lett; 1993 Aug; 329(1-2):178-82. PubMed ID: 8354392
[TBL] [Abstract][Full Text] [Related]
37. Fused Heterocyclic Compounds as Potent Indoleamine-2,3-dioxygenase 1 Inhibitors.
Panda S; Roy A; Deka SJ; Trivedi V; Manna D
ACS Med Chem Lett; 2016 Dec; 7(12):1167-1172. PubMed ID: 27994758
[TBL] [Abstract][Full Text] [Related]
38. Hypothesis: Metabolic targeting of 5-aminolevulinate synthase by tryptophan and inhibitors of heme utilisation by tryptophan 2,3-dioxygenase as potential therapies of acute hepatic porphyrias.
Badawy AA
Med Hypotheses; 2019 Oct; 131():109314. PubMed ID: 31443750
[TBL] [Abstract][Full Text] [Related]
39. Deletion of TDO2, IDO-1 and IDO-2 differentially affects mouse behavior and cognitive function.
Too LK; Li KM; Suarna C; Maghzal GJ; Stocker R; McGregor IS; Hunt NH
Behav Brain Res; 2016 Oct; 312():102-17. PubMed ID: 27316339
[TBL] [Abstract][Full Text] [Related]
40. A Role for Tryptophan-2,3-dioxygenase in CD8 T-cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma.
Greene LI; Bruno TC; Christenson JL; D'Alessandro A; Culp-Hill R; Torkko K; Borges VF; Slansky JE; Richer JK
Mol Cancer Res; 2019 Jan; 17(1):131-139. PubMed ID: 30143553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
